Related Experiment Video
Updated: Apr 28, 2026

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
Published on: September 16, 2019
Cancer immunotherapeutics: evolution of monoclonal antibodies to peptide immunogens
Ramachadran Murali1, Thomas Kieber-Emmons
11 Department of Biological Sciences, Cedars-Sinai Medical Center , Los Angeles, California.
Abstract:
The Wistar Institute under Hilary Koprowski's direction played a preeminent role in bringing the fruits of basic science to clinic through biotechnology and life science enterprises. Koprowski's early view on the utility of monoclonal antibodies has been validated to some extent, because monoclonal therapeutics form one of the fastest growing and most successful and lucrative segments within the biopharmaceutical sector. Over 30 monoclonal antibody drugs have now been approved in the United States and Europe. However, monoclonal antibodies might be viewed in the context of a bridge to the future for vaccines. The Wistar Institute's reputation, while built on vaccines for infectious diseases, can be translated in years to come into vaccines for cancer.
Insights
The Wistar Institute pioneered biotechnology, validating monoclonal antibodies for therapeutics. This success paves the way for future cancer vaccines, building on their infectious disease vaccine expertise.
Area of Science:
- Biotechnology and Life Sciences
- Biopharmaceutical Sector
- Vaccinology
Background:
- The Wistar Institute, under Hilary Koprowski, excelled in translating basic science into clinical applications via biotechnology and life science enterprises.
- Koprowski's early insights into monoclonal antibodies (mAbs) have been largely validated, with mAb therapeutics representing a rapidly expanding, successful, and profitable segment of the biopharmaceutical industry.
- Over 30 mAb drugs are now approved in the US and Europe, highlighting their therapeutic significance.
More Related Videos
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
Related Concept Videos
Tumor Immunotherapy
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...